drugset / Trial / NCT03799978

A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects

NCT03799978

Phase 1 Completed 20 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverOpen-labelOther

Summary

This is a single-center, open-label, randomized, two way crossover study to investigate the food effect on the pharmacokinetics of ACT-541468 in healthy male subjects.

Timeline

Start
2019-03-09
Primary completion
2019-03-18
Completion
2019-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 50 mg Oral

Indications

No indication recorded.